In a mouse bladder cancer tumor model, the antitumor effects of BCG immunotherapy were lost when CD4+ or CD8+ T cells were depleted, indicating their crucial role in the induced antitumor activity of BCG9. The gene discussed is CD8A; the disease is urinary bladder cancer.